{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:06:33Z","timestamp":1775235993228,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/leu.2016.363","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T07:41:44Z","timestamp":1480491704000},"page":"1603-1610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Casein kinase 2 controls the survival of normal thymic and leukemic \u03b3\u03b4 T cells via promotion of AKT signaling"],"prefix":"10.1038","volume":"31","author":[{"given":"S T","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tesio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J C","family":"Ribot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Macintyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J T","family":"Barata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Silva-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"BFleu2016363_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nri2820","volume":"10","author":"M Ciofani","year":"2010","unstructured":"Ciofani M, Z\u00fa\u00f1iga-Pfl\u00fccker JC . Determining \u03b3\u03b4 versus \u03b1\u03b2 T cell development. Nat Rev Immunol 2010; 10: 657\u2013663.","journal-title":"Nat Rev Immunol"},{"key":"BFleu2016363_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1126\/science.1103978","volume":"307","author":"B Silva-Santos","year":"2005","unstructured":"Silva-Santos B, Pennington DJ, Hayday AC . Lymphotoxin-mediated regulation of gammadelta cell differentiation by alphabeta T cell progenitors. Science 2005; 307: 925\u2013928.","journal-title":"Science"},{"key":"BFleu2016363_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1126\/science.1135344","volume":"315","author":"HJ Melichar","year":"2007","unstructured":"Melichar HJ, Narayan K, Der SD, Hiraoka Y, Gardiol N, Jeannet G et al. Regulation of gammadelta versus alphabeta T lymphocyte differentiation by the transcription factor SOX13. Science 2007; 315: 230\u2013233.","journal-title":"Science"},{"key":"BFleu2016363_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/ni.1717","volume":"10","author":"JC Ribot","year":"2009","unstructured":"Ribot JC, DeBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ et al. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat Immunol 2009; 10: 427\u2013436.","journal-title":"Nat Immunol"},{"key":"BFleu2016363_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.immuni.2009.07.010","volume":"31","author":"JPH Lauritsen","year":"2009","unstructured":"Lauritsen JPH, Wong GW, Lee S-Y, Lefebvre JM, Ciofani M, Rhodes M et al. Marked induction of the helix-loop-helix protein Id3 promotes the \u03b3\u03b4 T cell fate and renders their functional maturation Notch independent. Immunity 2009; 31: 565\u2013575.","journal-title":"Immunity"},{"key":"BFleu2016363_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.immuni.2013.01.010","volume":"38","author":"N Malhotra","year":"2013","unstructured":"Malhotra N, Narayan K, Cho OH, Sylvia KE, Yin C, Melichar H et al. A network of high-mobility group box transcription factors programs innate interleukin-17 production. Immunity 2013; 38: 681\u2013693.","journal-title":"Immunity"},{"key":"BFleu2016363_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.smim.2015.01.001","volume":"27","author":"N Schmolka","year":"2015","unstructured":"Schmolka N, Wencker M, Hayday AC, Silva-Santos B . Epigenetic and transcriptional regulation of \u03b3\u03b4 T cell differentiation: programming cells for responses in time and space. Semin Immunol 2015; 27: 19\u201325.","journal-title":"Semin Immunol"},{"key":"BFleu2016363_CR8","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4049\/jimmunol.1303119","volume":"192","author":"JC Ribot","year":"2014","unstructured":"Ribot JC, Ribeiro ST, Correia DV, Sousa AE, Silva-Santos B . Human \u03b3\u03b4 thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2\/IL-15 signaling. J Immunol 2014; 192: 2237\u20132243.","journal-title":"J Immunol"},{"key":"BFleu2016363_CR9","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","volume":"22","author":"AR Almeida","year":"2016","unstructured":"Almeida AR, Correia DV, Fernandes-Platzgummer A, da Silva CL, Gomes da Silva M, Anjos DR et al. Delta One T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/ differentiation and preclinical proof-of-concept. Clin Cancer Res 2016; 22: 5795\u20135804.","journal-title":"Clin Cancer Res"},{"key":"BFleu2016363_CR10","first-page":"264","volume":"90","author":"DM Matos","year":"2005","unstructured":"Matos DM, Rizzatti EG, Fernandes M, Buccheri V, Falc\u00e3o RP . Gammadelta and alphabeta T-cell acute lymphoblastic leukemia: comparison of their clinical and immunophenotypic features. Haematologica 2005; 90: 264\u2013266.","journal-title":"Haematologica"},{"key":"BFleu2016363_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1046\/j.1365-2141.1998.00774.x","volume":"101","author":"G Schott","year":"1998","unstructured":"Schott G, Sperling C, Schrappe M, Ratei R, Martin M, Meyer U et al. Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukaemia. Br J Haematol 1998; 101: 753\u2013755.","journal-title":"Br J Haematol"},{"key":"BFleu2016363_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.leu.2404957","volume":"22","author":"M van Grotel","year":"2008","unstructured":"van Grotel M, Meijerink JPP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JGCAM et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008; 22: 124\u2013131.","journal-title":"Leukemia"},{"key":"BFleu2016363_CR13","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2009-10-248054","volume":"116","author":"M Shehata","year":"2010","unstructured":"Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K\/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010; 116: 2513\u20132521.","journal-title":"Blood"},{"key":"BFleu2016363_CR14","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1182\/blood-2010-04-277947","volume":"116","author":"LR Martins","year":"2010","unstructured":"Martins LR, L\u00facio P, Silva MC, Anderes KL, Gameiro P, Silva MG et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724\u20132731.","journal-title":"Blood"},{"key":"BFleu2016363_CR15","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2005-11-013672","volume":"108","author":"FA Piazza","year":"2006","unstructured":"Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698\u20131707.","journal-title":"Blood"},{"key":"BFleu2016363_CR16","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3324\/haematol.2013.096438","volume":"99","author":"A Margarida Gomes","year":"2014","unstructured":"Margarida Gomes A, Soares MVD, Ribeiro P, Caldas J, P\u00f3voa V, Martins LR et al. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K\/Akt pathway despite high PTEN protein levels. Haematologica 2014; 99: 1062\u20131068.","journal-title":"Haematologica"},{"key":"BFleu2016363_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2015-06-651505","volume":"126","author":"C Song","year":"2015","unstructured":"Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan B et al. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic ef fi cacy in high-risk leukemia. Blood 2015; 126: 1813\u20131823.","journal-title":"Blood"},{"key":"BFleu2016363_CR18","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1172\/JCI34616","volume":"118","author":"A Silva","year":"2008","unstructured":"Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762\u20133774.","journal-title":"J Clin Invest"},{"key":"BFleu2016363_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/leu.2013.349","volume":"28","author":"F Buontempo","year":"2014","unstructured":"Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F et al. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia 2014; 28: 543\u2013553.","journal-title":"Leukemia"},{"key":"BFleu2016363_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/leu.2011.385","volume":"26","author":"F Piazza","year":"2012","unstructured":"Piazza F, Manni S, Ruzzene M, Pinna LA, Gurrieri C, Semenzato G . Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012; 26: 1174\u20131179.","journal-title":"Leukemia"},{"key":"BFleu2016363_CR21","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.4049\/jimmunol.1200065","volume":"189","author":"CM Sestero","year":"2012","unstructured":"Sestero CM, McGuire DJ, De Sarno P, Brantley EC, Soldevila G, Axtell RC et al. CD5-dependent CK2 activation pathway regulates threshold for T cell anergy. J Immunol 2012; 189: 2918\u20132930.","journal-title":"J Immunol"},{"key":"BFleu2016363_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ni.3083","volume":"16","author":"A Ulges","year":"2015","unstructured":"Ulges A, Klein M, Reuter S, Gerlitzki B, Hoffmann M, Grebe N et al. Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. Nat Immunol 2015; 16: 267\u2013275.","journal-title":"Nat Immunol"},{"key":"BFleu2016363_CR23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.4049\/jimmunol.1200268","volume":"189","author":"JC Ribot","year":"2012","unstructured":"Ribot JC, Debarros A, Mancio-Silva L, Pamplona A, Silva-Santos B . B7-CD28 costimulatory signals control the survival and proliferation of murine and human \u03b3\u03b4 T cells via IL-2 production. J Immunol 2012; 189: 1202\u20131208.","journal-title":"J Immunol"},{"key":"BFleu2016363_CR24","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2009-10-250258","volume":"116","author":"M Buitenhuis","year":"2010","unstructured":"Buitenhuis M, Van Der Linden E, Ulfman LH, Hofhuis FM, Bierings MB, Coffer PJ . Protein kinase B (PKB\/c-akt) regulates homing of hematopoietic progenitors through modulation of their adhesive and migratory properties. Blood 2010; 116: 2373\u20132384.","journal-title":"Blood"},{"key":"BFleu2016363_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.18632\/oncotarget.1513","volume":"5","author":"LR Martins","year":"2014","unstructured":"Martins LR, Perera Y, L\u00facio P, Silva MG, Perea SE, Barata JT . Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor. Oncotarget 2014; 5: 258\u2013263.","journal-title":"Oncotarget"},{"key":"BFleu2016363_CR26","doi-asserted-by":"publisher","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","volume":"70","author":"A Siddiqui-Jain","year":"2010","unstructured":"Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O\u2019Brien SE et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010; 70: 10288\u201310298.","journal-title":"Cancer Res"},{"key":"BFleu2016363_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1517\/13543776.2012.717615","volume":"22","author":"G Cozza","year":"2012","unstructured":"Cozza G, Pinna LA, Moro S . Protein kinase CK2 inhibitors: a patent review. Expert Opin Ther Pat 2012; 22: 1081\u20131097.","journal-title":"Expert Opin Ther Pat"},{"key":"BFleu2016363_CR28","first-page":"1","volume":"9","author":"H Kim","year":"2014","unstructured":"Kim H, Choi K, Kang H, Lee SY, Chi SW, Lee MS et al. Identification of a novel function of CX-4945 as a splicing regulator. PLoS One 2014; 9: 1\u20138.","journal-title":"PLoS One"},{"key":"BFleu2016363_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1242\/dmm.025668","volume":"9","author":"H Kim","year":"2016","unstructured":"Kim H, Lee K-S, Kim A-K, Choi M, Choi K, Kang M et al. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition. Dis Model Mech 2016; 9: 839\u2013848.","journal-title":"Dis Model Mech"},{"key":"BFleu2016363_CR30","doi-asserted-by":"publisher","first-page":"24246","DOI":"10.1074\/jbc.M314298200","volume":"279","author":"M Muraki","year":"2004","unstructured":"Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T et al. Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks. J Biol Chem 2004; 279: 24246\u201324254.","journal-title":"J Biol Chem"},{"key":"BFleu2016363_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.abb.2010.12.024","volume":"507","author":"T Adayev","year":"2011","unstructured":"Adayev T, Wegiel J, Hwang YW . Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). Arch Biochem Biophys 2011; 507: 212\u2013218.","journal-title":"Arch Biochem Biophys"},{"key":"BFleu2016363_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.advenzreg.2010.09.012","volume":"51","author":"JT Barata","year":"2011","unstructured":"Barata JT . The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2011; 51: 37\u201349.","journal-title":"Adv Enzyme Regul"},{"key":"BFleu2016363_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00015","volume":"6","author":"ST Ribeiro","year":"2015","unstructured":"Ribeiro ST, Ribot JC, Silva-Santos B . Five layers of receptor signaling in \u03b3\u03b4 T-cell differentiation and activation. Front Immunol 2015; 6: 1\u20139.","journal-title":"Front Immunol"},{"key":"BFleu2016363_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/eji.201040905","volume":"41","author":"A DeBarros","year":"2011","unstructured":"DeBarros A, Chaves-Ferreira M, D\u2019Orey F, Ribot JC, Silva-Santos B . CD70\u2013CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human \u03b3\u03b4 peripheral blood lymphocytes. Eur J Immunol 2011; 41: 195\u2013201.","journal-title":"Eur J Immunol"},{"key":"BFleu2016363_CR35","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/MCB.00319-13","volume":"33","author":"N Patsoukis","year":"2013","unstructured":"Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA . PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting CK2. Mol Cell Biol 2013; 33: 3091\u20133098.","journal-title":"Mol Cell Biol"},{"key":"BFleu2016363_CR36","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1517\/13543784.2010.520701","volume":"19","author":"SK Pal","year":"2010","unstructured":"Pal SK, Reckamp K, Yu H, Figlin RA . Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010; 19: 1355\u20131366.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFleu2016363_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood-2006-07-037572","volume":"111","author":"M Buitenhuis","year":"2008","unstructured":"Buitenhuis M, Verhagen LP, van Deutekom HWM, Castor A, Verploegen S, Koenderman L et al. Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 2008; 111: 112\u2013121.","journal-title":"Blood"},{"key":"BFleu2016363_CR38","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1007\/s00018-009-9154-y","volume":"66","author":"JH Trembley","year":"2009","unstructured":"Trembley JH, Wang G, Unger G, Slaton J, Ahmed K . CK2: A key player in cancer biology. Cell Mol Life Sci 2009; 66: 1858\u20131867.","journal-title":"Cell Mol Life Sci"},{"key":"BFleu2016363_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20021469","volume":"369","author":"DW Litchfield","year":"2003","unstructured":"Litchfield DW . Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369: 1\u201315.","journal-title":"Biochem J"},{"key":"BFleu2016363_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/mi.2012.57","volume":"6","author":"S Koch","year":"2012","unstructured":"Koch S, Capaldo CT, Hilgarth RS, Fournier B, Parkos CA, Nusrat A . Protein kinase CK2 is a critical regulator of epithelial homeostasis in chronic intestinal inflammation. Mucosal Immunol 2012; 6: 136\u2013145.","journal-title":"Mucosal Immunol"},{"key":"BFleu2016363_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2005.04.003","volume":"22","author":"MC Haks","year":"2005","unstructured":"Haks MC, Lefebvre JM, Lauritsen JPH, Carleton M, Rhodes M, Miyazaki T et al. Attenuation of gammadeltaTCR signaling efficiently diverts thymocytes to the alphabeta lineage. Immunity 2005; 22: 595\u2013606.","journal-title":"Immunity"},{"key":"BFleu2016363_CR42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2005.03.014","volume":"22","author":"SM Hayes","year":"2005","unstructured":"Hayes SM, Li L, Love PE . TCR signal strength influences alphabeta\/gammadelta lineage fate. Immunity 2005; 22: 583\u2013593.","journal-title":"Immunity"},{"key":"BFleu2016363_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coi.2005.01.009","volume":"17","author":"DJ Pennington","year":"2005","unstructured":"Pennington DJ, Silva-Santos B, Hayday AC . \u03b3\u03b4 T cell development\u2014having the strength to get there. Curr Opin Immunol 2005; 17: 108\u2013115.","journal-title":"Curr Opin Immunol"},{"key":"BFleu2016363_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/ni.3424","volume":"17","author":"M Mu\u00f1oz-Ruiz","year":"2016","unstructured":"Mu\u00f1oz-Ruiz M, Ribot JC, Grosso AR, Gon\u00e7alves-Sousa N, Pamplona A, Pennington DJ et al. TCR signal strength controls thymic differentiation of discrete proinflammatory \u03b3\u03b4 T cell subsets. Nat Immunol 2016; 17: 721\u2013728.","journal-title":"Nat Immunol"},{"key":"BFleu2016363_CR45","first-page":"95","volume":"32","author":"EA Macintyre","year":"1990","unstructured":"Macintyre EA, Salloum E, Sigaux F . Comparison of alpha beta and gamma delta expressing CD3+ acute lymphoblastic leukemias. Nouv Rev Fr H\u00e9matol 1990; 32: 95\u201399.","journal-title":"Nouv Rev Fr H\u00e9matol"},{"key":"BFleu2016363_CR46","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/sj.cdd.4401604","volume":"12","author":"G Di Maira","year":"2005","unstructured":"Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al. Protein kinase CK2 phosphorylates and upregulates Akt\/PKB. Cell Death Differ 2005; 12: 668\u2013677.","journal-title":"Cell Death Differ"},{"key":"BFleu2016363_CR47","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/jcp.22527","volume":"226","author":"DP Ponce","year":"2011","unstructured":"Ponce DP, Maturana JL, Cabello P, Yefi R, Niechi I, Silva E et al. Phosphorylation of AKT\/PKB by CK2 is necessary for the AKT-dependent up-regulation of \u03b2-catenin transcriptional activity. J Cell Physiol 2011; 226: 1953\u20131959.","journal-title":"J Cell Physiol"},{"key":"BFleu2016363_CR48","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.1038\/sj.onc.1209097","volume":"24","author":"DR Plas","year":"2005","unstructured":"Plas DR, Thompson CB . Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005; 24: 7435\u20137442.","journal-title":"Oncogene"},{"key":"BFleu2016363_CR49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1042\/BJ20150041","volume":"468","author":"G Risso","year":"2015","unstructured":"Risso G, Blaustein M, Pozzi B, Mammi P, Srebrow A . Akt\/PKB: one kinase, many modifications. Biochem J 2015; 468: 203\u2013214.","journal-title":"Biochem J"},{"key":"BFleu2016363_CR50","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA . Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785\u2013789.","journal-title":"Nature"},{"key":"BFleu2016363_CR51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.leukres.2012.10.016","volume":"37","author":"F Piazza","year":"2013","unstructured":"Piazza F, Manni S, Semenzato G . Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3. Leuk Res 2013; 37: 221\u2013227.","journal-title":"Leuk Res"},{"key":"BFleu2016363_CR52","doi-asserted-by":"publisher","first-page":"12105","DOI":"10.1073\/pnas.0705285104","volume":"104","author":"MM Juntilla","year":"2007","unstructured":"Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA . Akt1 and Akt2 are required for alphabeta thymocyte survival and differentiation. Proc Natl Acad Sci USA 2007; 104: 12105\u201312110.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016363_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos B, Serre K, Norell H . \u03b3\u03b4 T cells in cancer. Nat Rev Immunol 2015; 15: 683\u2013691.","journal-title":"Nat Rev Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2016363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016363","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:06:39Z","timestamp":1684433199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFleu2016363"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.363","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]},"assertion":[{"value":"17 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BSS is co-founder and share holder of Lymphact SA. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}